Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + axitinib + sintilimab for recurrent renal cell carcinoma after nephrectomy
ChiCTR2100049523Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and sintilimab in renal cell carcinoma (RCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 1-year progression-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
axitinibsintilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2100049523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049523.